News | May 05, 2022
Promising new universal coronavirus vaccine candidate discovered
Formula attenuates 99% of 365 coronaviruses in computer models
Formula attenuates 99% of 365 coronaviruses in computer models
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
The Blockchain-based solution was awarded the 2021 Bionow Technical Service Award
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
The expansion makes Exothera one of the largest viral vector facilities in Europe
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Subscribe To Our Newsletter & Stay Updated
